Treprostinil
Pulmonary hypertension year in review: Inhaled therapy, improving mortality trends in US
The Healio Editors compiled the most-read pulmonary hypertension news published in 2021.
Treatment options expanding for progressive fibrosing ILD
A speaker at the PFF Summit highlighted recent trials and therapeutic updates for progressive fibrosing interstitial lung disease.
Differences in hospitalization-related costs with oral PAH therapies
Treatment with selexipag could save payers costs over 2 years compared with oral treprostinil, according to results of a comparative cost model reported at the Academy of Managed Care Pharmacy virtual meeting.
Multiple disease progression events less likely with continued inhaled treprostinil
In a post hoc analysis of the INCREASE study, patients with interstitial lung disease-associated pulmonary hypertension who continued inhaled treprostinil were less likely to experience further disease progression events vs. placebo.
Risk stratification, improved therapies important in PAH
For physicians, pulmonary artery hypertension poses many challenges, including the need for greater awareness and better therapies, according to an expert who spoke with Healio.
Recent pulmonary hypertension updates: New therapies, women’s health and more
The Healio Editors have compiled a list of recent articles about pulmonary hypertension in recognition of World Pulmonary Hypertension Day.
FDA approves inhaled treprostinil for pulmonary hypertension associated with ILD
The FDA approved inhaled treprostinil for the treatment of patients with pulmonary hypertension associated with interstitial lung disease, according to a press release from United Therapeutics.
Updates in pulmonary hypertension treatments, FDA approvals and more from 2020
The Healio editors have compiled a list of the most-read pulmonary arterial hypertension news published in 2020.
Recent updates in pulmonary hypertension: New treatment options, inhaled therapy and more
The Healio editors have compiled a list of recent updates in the management and treatment of pulmonary hypertension.
Inhaled treprostinil improves QOL, other exploratory outcomes in patients with PAH
New exploratory endpoint data from the INSPIRE study show improvements after 2 months of treatment with inhaled treprostinil in quality of life, 6-minute walk distance and New York Heart Association functional class.